Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IMV Inc IMVIF

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.


GREY:IMVIF - Post by User

IMV Inc
Bullboard Posts
User Avatar Image
(2)
•••
Comment by europe10on Mar 26, 2019 10:30am
92 Views
Post# 29536269

RE:Thoughts on prelim data

RE:Thoughts on prelim dataThe results confirm that the stock pullback was not related to bad clinical results, but to a bad management of Nasdaq listing and financing.
I assume insiders could not buy before this release?
It appears IMV is advancing, but will shareholders benefit?
If the stock does not run on good test results it will drift down again and next financing will be at ..... 3$, then at 1$.......and IMV is in two years time bought out at 3$...?
Merck results and stock market reaction will be crucial
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities